Biotechnology

Immunovant

Immunovant released FY2026 Annual Earnings on May 20 Pre-Market (EST), Actual Revenue USD 0 (Forecast USD 0), Actual EPS USD -2.7716 (Forecast USD -2.6143)

Immunovant released FY2026 Q4 earnings on May 20 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7258 (forecast USD -0.5979)

Immunovant to Release FY2026 Q4 Earnings on May 20 Pre-Market EST, Forecast EPS -0.5979 USD

Oppenheimer Analyst Maintains Buy Rating on Immunovant with $54 Price Target

Immunovant Reports Significant Results for Brepocitinib in Dermatomyositis Study

Immunovant released FY2026 9 Months Earnings on February 6 Pre-Market EST, actual revenue USD 0, actual EPS USD -2.0438

Immunovant released FY2026 Q3 earnings on February 6 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6099 (forecast USD -0.7082)

Immunovant to Release FY2026 Q3 Earnings on February 6, Pre-Market EST, Forecast EPS: USD -0.7082

Roivant Sciences Ltd. Acquires Immunovant Inc.

Goldman Sachs Analyst Maintains Hold Rating on Immunovant

Immunovant Inc. Announces the Underwritten Public Offering Pricing of Its Common Stock

Analyst Maintains Immunovant Buy Rating, Price Target at $50

Immunovant released FY2026 Q2 earnings during market hours on November 10 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7285 (forecast USD -0.7179)

Immunovant released FY2026 Semi-Annual Earnings on November 10 During-Market (EST), actual revenue USD 0, actual EPS USD -1.4342

Immunovant to Release FY2026 Q2 Earnings on November 10, Pre-Market EST, Forecast EPS USD -0.7179

Immunovant Executives Stout Jay and Michael Geffner Sold Stocks to Pay Tax Obligations

Immunovant Inc. CMO Reports Disposition of Common Stock

Immunovant released FY2026 Q1 earnings on August 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7058 (forecast USD -0.6914)

Immunovant Inc. CTO Reports Common Stock Disposition

Immunovant Investigated for Private Placement Deal

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Akanda

Netcapital

Agape ATP

NewGenIvf

Tradr 2X Long QBTS Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Tradr 2X Long RGTI Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Earning Release

业绩披露

2026.05.20 (EST) Announced FY2026 Q4 Earning Release (USD) Revenue 0, Net Income -147.86 M, EPS -0.7258

IMVT

Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&D expenses rose to $142.3 million. Analysts adjusted price targets, with HC Wainwright raising it from $35 to $40 and B of A Securities from $32 to $43. Immunovant shares fell 5% to $33.76.

benzinga_article

These Analysts Increase Their Forecasts On Immunovant After Q4 Results

Immunovant's stock (NASDAQ:IMVT) fell 6.4% to $33.2950 after reporting disappointing quarterly earnings of ($0.73) EPS, missing estimates by ($0.13). Despite this, the company has a strong cash balance of $902 million and positive developments in clinical trials. Analysts have mixed ratings, with six 'Buy' and one 'Sell' rating. Insider transactions showed significant share sales to cover tax obligations.

Market Beat

Abrdn plc

Immunovant (NASDAQ:IMVT) Stock Price Down 6.4% on Disappointing Earnings

ROIV

LABU

Yesterday, Roivant Sciences' stock price surged by 14.89%, with a trading volume of $541 million, showing a significant increase in volume and clear signs of capital inflow. The MACD daily line confirmed a bullish signal above the zero axis, combined with a double-digit single-day increase and massive trading volume, indicating that the short-term bullish momentum has entered an accelerated release phase. The stock price broke through the upper boundary of the previous consolidation range, with the 5-day moving average sharply turning upward, completing the transition from a nascent bullish pattern to an established one within a single day. The overall market displayed a typical breakout acceleration pattern. On the news front, the biotechnology sector performed impressively yesterday, with Immunovant in the same sector soaring by 35.26%, reflecting a significant rebound in market enthusiasm for innovative drug pipelines and platform-based biotechnology companies. Roivant Sciences, as a platform company focused on incubating and accelerating biopharmaceutical subsidiaries, has its valuation highly linked to pipeline progress. Currently, the risk appetite in the U.S. stock market is warming up, with the S&P 500 index stabilizing at $741 (SPY), and capital rotation in the technology and healthcare sectors providing a favorable market environment for growth-oriented biotechnology stocks. The hawkish minutes from the Federal Reserve have not significantly suppressed the growth sector in the short term. From a technical perspective, the bottom area of yesterday's large bullish candlestick forms strong short-term support. If today's opening can maintain two-thirds of that line, the probability of continuing the bullish trend is relatively high. However, a 15% single-day increase means that overbought indicators like RSI have triggered warnings, and there is a considerable chance of profit-taking during the session

Technical Forecast

Roivant Sciences

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

S&P 500

Pre-market trend | Roivant Sciences (ROIV) surged nearly 15% on 5/20, is there a surge of funds into biotechnology?

Yesterday, Immunovant's stock price surged by 35.26%, with a trading volume of USD 663 million, reaching a recent record high, and the market's enthusiasm for this biotech stock was nearly frenzied. The MACD daily line formed a bullish signal above the zero axis, combined with such an astonishing single-day increase and high trading volume, is typically seen as a strong signal for establishing a phase trend reversal. The stock price broke through the consolidation range of the previous weeks, with the 5-day and 10-day moving averages left far behind, indicating an explosive release of short-term bullish momentum. Such a level of volume breakout in the biotech sector often corresponds to significant catalyst-driven events. From an industry perspective, the capital activity in the biotech sector has significantly increased recently, with Roivant Sciences also rising sharply by 14.89% yesterday, as market attention on innovative drug pipelines continues to grow. Immunovant focuses on FcRn antibody therapy, and its clinical progress in autoimmune diseases may be the core driving force behind this surge. Currently, the overall risk appetite in the U.S. stock market is warming up, with the S&P 500 ETF rising by 1.02%, and both the technology and biotech sectors strengthening, providing a favorable external environment for small and mid-cap growth stocks. Although the Federal Reserve's meeting minutes were hawkish, the market chose to pursue growth logic in the short term. Technically, yesterday's massive long bullish line itself constituted a strong short-term support reference, but the 35% single-day increase also indicates that short-term technical indicators are severely overbought. If trading volume quickly shrinks after the market opens today, the probability of a pullback after a high will significantly increase

SPDR S&P 500

Pre-market trend | Immunovant (IMVT) surged 35% on May 20, can it continue after the breakout?

Immunovant (IMVT) has gained attention following strong Week 16 data for its IMVT-1402 rheumatoid arthritis trial, resulting in a 35.26% share price increase and a 144.23% total return over the past year. The stock is considered modestly undervalued at a fair value of $41.13, despite ongoing losses. The current P/B ratio of 8.5x suggests a premium over the sector, raising risks if trial results disappoint. Investors are encouraged to review the data and consider potential mispricings in the market.

Simplywall

Assessing Immunovant (IMVT) Valuation After Strong IMVT-1402 Data And Refocused Pipeline Strategy

HCWB

SLXN

In today's market updates, HCW Biologics surged 129% amid concerns over its financial viability. Silexion is set to begin a Phase 2/3 trial for SIL204, gaining 96.95%. Immunovant's IMVT-1402 showed promising results in rheumatoid arthritis, rising 35.26%. Claritev Corp. reported Q1 revenue growth and expects 2026 revenue between $985 million and $1 billion, up 31.11%. Black Diamond Therapeutics is presenting trial results soon, while Modular Medical is transitioning to commercial operations.

rttnews

HCW Biologics

Silexion Therapeutics

VG Health

Claritev

MindWalk

Black Diamond Therapeutics

Modular Medical

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM)

CLARITEV CORPORATION C/WTS 08/10/2025(TO PUR COM)

SLXN On Track, IMVT Hits New High, CTEV Eyes Blockbuster Revenue, Big Day Ahead For BDTX

Immunovant, Inc.'s stock price target has been raised from $40.29 to $42.55, indicating a potential upside of 62%. This estimate comes from 11 analysts, with price forecasts ranging from $23 to $66 per share. The consensus rating remains a 'Buy' with 8 Buys, 4 Holds, and no Sells.

TradingView

Factset Research

Immunovant, Inc. Stock 12‑Month Price Target Raised to $42.55, Implies 62% Upside

XNDU

NVTS

ALAB

FCEL

HIVE

KURA

Immunovant(IMVT) rose 35.26%, with a trading turnover 669.9 Million USD, and a year-to-date rose 39.9%. T1 Energy(TE) rose 26.45%, with a trading turnover 910.4 Million USD, and a year-to-date rose 30.2%. Xanadu Quantum Tech - B(XNDU) rose 20.56%, with a trading turnover 110.8 Million USD, and a year-to-date rose 31.2%.

Immunovant(IMVT.US)